|
Regulatory
"Sunshine" Continues to Exempt CME Funding
A federal policy issued late last week appeared to deal a serious blow to continuing medical education programs supported by biopharma companies. But the specifics published by the Centers for Medicare and Medicaid Services on Oct. 31, 2014 actually continue to exempt independent CME funding from the Open Payments reporting requirements for transfers of value from manufacturers to prescribers. Jill Wechsler reports ...Read more
Harness the power of your oncology data - Using data to produce customer insights through analytics is particularly challenging in oncology.  Read this article
learn how companies have captured the power of their oncology data and produced the right analytics to drive business results.
Event
Sparks Fly at Prix Galien on US Health Reform
The absence of Sanofi chief Christopher Viehbacher loomed over the Prix Galien Forum last week, especially during the event’s most contentious panel on US Healthcare Reform. Regarding the US healthcare system, “Everything is under tension right now,” said Viehbacher’s Sanofi stand-in, Elias Zerhouni ...Read more
Europe
So Who’s in Charge of Medicines in Brussels?
Now we know who is to do what regarding health issues in the new European Commission. Or do we? The furore that the new boss of the commission, Jean-Claude Juncker, unleashed with the plans for his new team, weeks before it took office, is still reverberating around Brussels. Peter O’ Donnell reports on the fallout ...Read more
Covance MarketPlace. Connect Right from the Start.
Find the right partner with the desire and resources to help you realize your molecule’s potential. Through our private, secure and exclusive online portal, you can share information about your molecule to potential investors or partners. It's one more innovative way to transform the profile and success of your program, delivered by the only global drug development partner with expertise spanning preclinical, clinical and commercial phases.  Learn more
Executive Interview
Dane in America: Novo Nordisk’s Jesper Hoiland
Novo Nordisk's Senior VP for North America, Jesper Hoiland, talks to Pharm Exec’s William Looney about his first year on the job at Novo's regional HQ in Princeton, NJ, including an unsettling initial encounter with pharmacy benefit manager (PBM) medicines gatekeepers
...Read more
R&D
We Must Rock the Boat if We Want Research to Soar
Innovation is for the bold, but the pharmaceutical research industry is restrained by risk aversion and the perceived fear of regulatory repercussions — new ideas are fine as long as we don’t deviate from the tried, true, and duly SOP’d order sanctioned by our regulatory department and quality assurance auditors. Wayne Kubick suggests it’s time to rock the boat
...Read more
 |
